Vical releases Vaxfactin results; Merck and Biogen boost NC job market;

Vaccine Research

Vical announced positive results from a Phase I trial of Vaxfectin, the company's H1N1 pandemic flu vaccine, that showed the vaccine was well tolerated. The adjuvant has also tested well in a H5N1 vaccine. Vical release

Vaccine Market

Compass Biotechnologies and Cambridge, UK-based Arecor will work together to develop a heat stable hepatitis B vaccine using Arecor's Arestat technology. Compass release

Thanks to new facilities around Durham, NC, Merck and Biogen will each add employees to staff their new sites. Merck expects to hire another 150 people to its 450 already employed at Treyburn Corporate Park; Biogen employs 275 at Research Triangle Park and has not disclosed how many more workers it will hire. News

Merck and Qiagen are joining forces to combat cervical cancer in Rwanda. The companies will provide 2 million doses of Merck's Gardasil and 250,000 screening tests to the country for free. Article

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.